Azoospermia due to drug therapy
ICD-10 N46.021 is a billable code used to indicate a diagnosis of azoospermia due to drug therapy.
Azoospermia is defined as the absence of sperm in the ejaculate, which can significantly impact male fertility. When azoospermia is attributed to drug therapy, it typically involves medications that affect hormonal balance, spermatogenesis, or sperm transport. Common drug classes that may lead to this condition include certain antihypertensives, anabolic steroids, and chemotherapeutic agents. The pathophysiology often involves disruption of the hypothalamic-pituitary-gonadal axis, leading to decreased testosterone levels and impaired sperm production. Clinically, patients may present with infertility, and a thorough evaluation including hormonal assays, semen analysis, and a detailed medication history is essential. Management may involve discontinuation of the offending agent, hormonal therapy, or assisted reproductive technologies depending on the underlying cause and duration of azoospermia. Understanding the relationship between drug therapy and male infertility is crucial for effective diagnosis and treatment.
Detailed patient history, including medication use, hormonal levels, and semen analysis results.
Evaluation of male infertility, management of testicular disorders, and treatment of orchitis.
Urologists must ensure that the link between drug therapy and azoospermia is clearly documented to support the diagnosis.
Hormonal assays, detailed patient history, and assessment of endocrine function.
Management of hormonal imbalances affecting fertility and evaluation of drug-induced endocrine disorders.
Endocrinologists should document any hormonal treatments that may influence sperm production.
Used to evaluate male infertility in patients suspected of azoospermia.
Results of the semen analysis must be documented in the patient's medical record.
Urologists and reproductive endocrinologists should ensure that the analysis is comprehensive.
The primary cause of azoospermia coded as N46.021 is drug therapy, which can disrupt normal sperm production and hormonal balance.
